Skip to main content
B

Baotou Dongbao Bio-Tech Co.,Ltd. — Investor Relations & Filings

Ticker · 300239 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,067 across all filing types
Latest filing 2026-04-23 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300239

About Baotou Dongbao Bio-Tech Co.,Ltd.

https://www.dongbaoshengwu.com

Baotou Dongbao Bio-Tech Co.,Ltd. specializes in the research, development, production, and distribution of gelatin and collagen-based products. The company’s primary portfolio includes medicinal gelatin, edible gelatin, and high-purity collagen peptides. These products serve diverse applications across the pharmaceutical, food, and health supplement sectors. Specifically, its medicinal gelatin is utilized in the manufacturing of hard and soft capsules, while its edible gelatin is a key ingredient in confectionery and dairy products. The company also focuses on hydrolyzed collagen for use in functional foods and cosmetic formulations. By leveraging advanced biotechnology and large-scale manufacturing capabilities, the firm provides specialized solutions for protein-based ingredients, emphasizing quality control and technical innovation in the field of animal-derived protein processing.

Recent filings

Filing Released Lang Actions
第九届董事会第十六次会议决议公告
Regulatory Filings Classification · 1% confidence The document is a Chinese board meeting resolution announcement (“第九届董事会第十六次会议决议公告”) describing the convocation, attendance, and resolutions (including approving the Q1 2026 report) of a Board of Directors meeting. It is not the full quarterly report itself (IR), nor a simple announcement of report publication (RPA) or management discussion (MDA), nor is it announcing changes in board composition (MANG). It falls under general regulatory announcements that do not fit a more specific category, so it should be classified as a Regulatory Filing (RNS).
2026-04-23 Chinese
2026年一季度报告
Interim / Quarterly Report Classification · 1% confidence The document is titled '包头东宝生物技术股份有限公司2026年第一季度报告' (Baotou Dongbao Bio-Tech Co., Ltd. 2026 First Quarter Report). It contains comprehensive financial statements including the balance sheet, income statement, and cash flow statement for the first quarter of 2026. It is a substantive financial report rather than an announcement or a summary, fitting the definition of an Interim/Quarterly Report (IR). Q1 2026
2026-04-23 Chinese
关于召开2025年度股东会的提示性公告
AGM Information Classification · 1% confidence The document is a detailed notice (“提示性公告”) for the company’s 2025 annual shareholders’ meeting, specifying the meeting date, agenda items (including the board report, profit distribution plan, election of directors, etc.), voting procedures (on-site and online), registration requirements, and related attachments. This clearly falls under materials shared in connection with an Annual General Meeting rather than financial results or other regulatory filings. Therefore, it is classified as AGM Information.
2026-04-23 Chinese
招商证券股份有限公司关于包头东宝生物技术股份有限公司向不特定对象发行可转换公司债券之持续督导保荐总结报告书
Regulatory Filings
2026-04-09 Chinese
招商证券股份有限公司关于包头东宝生物技术股份有限公司2025年度跟踪报告
Regulatory Filings
2026-04-09 Chinese
招商证券股份有限公司关于包头东宝生物技术股份有限公司2025年度定期现场检查报告
Regulatory Filings
2026-04-09 Chinese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.